Medical Marijuana for Crohn's Disease in Florida
Inflammatory bowel disease causing chronic digestive tract inflammation and pain.
Medically reviewed by Bruce Stratt, MD
Board-Certified Physician · OMMU Certified · Boca Raton, FL
Overview
Crohn's Disease is a chronic inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract, though it most commonly involves the colon and ileum. It causes ulcers in the intestinal lining, resulting in chronic diarrhea (sometimes with blood), severe abdominal pain and cramping, weight loss, fatigue, fever, and malnutrition. The disease follows unpredictable cycles of remission and flare-ups — sometimes going quiet for extended periods before returning with full force.
Crohn's is thought to be an autoimmune disorder where the body attacks its own healthy intestinal tissues. The gastrointestinal tract contains one of the highest concentrations of endocannabinoid receptors in the body — CB2 receptors are expressed on intestinal epithelial cells, Paneth cells, macrophages, and regulatory T cells. Research has also found that endocannabinoid (anandamide) levels are significantly lower in inflamed IBD mucosa, suggesting an endocannabinoid deficiency in active disease that cannabinoid therapy may help correct.
Common medical treatments mostly involve steroids and immunosuppressive drugs, which carry significant long-term side effects and cannot be used indefinitely without posing serious health risks. Newer biologic drugs like Remicade and Humira offer more targeted treatment but can cost $30,000–$50,000 per year and still fail to achieve remission in many patients. For many Crohn's patients, conventional treatments provide only limited symptom control, making alternative approaches critically important for quality of life.
How Medical Cannabis May Help
Research results for cannabis and Crohn's disease have been remarkable. A landmark prospective, placebo-controlled study (Naftali et al., Clinical Gastroenterology and Hepatology, 2013) randomized 21 Crohn's patients who had failed steroids, immunomodulators, and anti-TNF-alpha therapy. After eight weeks, 90% (10/11) of the cannabis group achieved clinical response (CDAI decrease >100 points) compared to 40% (4/10) on placebo. Complete remission (CDAI <150) was achieved in 45% of the cannabis group versus only 10% on placebo. No significant side effects were reported. Medical cannabis reduces intestinal inflammation through CB2 receptor activation, which enhances regulatory T cell suppressive function and increases anti-inflammatory IL-10 secretion while reducing pro-inflammatory cytokines like TNF-alpha. Cannabis also decreases intestinal motility (reducing diarrhea frequency), stimulates appetite to combat malnutrition, and provides meaningful relief from abdominal pain and cramping through both central and peripheral pain pathways. A follow-up study (Naftali et al., 2017) tested low-dose CBD alone and found it insufficient for Crohn's symptom relief, suggesting THC is the key active component. This is an important distinction for patients — CBD-only products may not provide adequate relief for IBD, and THC-containing formulations appear necessary for the strongest therapeutic effects. Dr. Stratt will evaluate your specific disease severity, current medications, and symptom profile to recommend an appropriate cannabis formulation. Many patients find cannabis most effective when used alongside their gastroenterologist-prescribed medications rather than as a replacement.
Individual results vary. Consult with Dr. Stratt to understand how cannabis therapy may apply to your specific situation.
What to Bring to Your Appointment
Bring a valid Florida ID and gastroenterology records confirming Crohn's Disease diagnosis, colonoscopy or imaging reports, and a list of current medications including biologics or immunosuppressants.
Frequently Asked Questions
Related Articles
Patient Resources
Get Your Medical Marijuana Card for Crohn's Disease
Schedule your evaluation with Dr. Stratt. Same-day state registry submissions for qualifying patients.